# U S Physical Therapy Inc: Form 10-Q for the period ended Sep 30, 2019

- Company: [U S Physical Therapy Inc](/companies/usph.md) (CIK 885978)
- Form: 10-Q
- Filed: 2019-11-08
- Accepted by EDGAR: Nov 8, 2019, 14:31 ET
- Period: 2019-09-30
- Accession: 0001140361-19-020161
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/885978/000114036119020161/form10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/885978/000114036119020161/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2019-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2019-07-01 to 2019-09-30 | $117.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2019-01-01 to 2019-09-30 | $359.9m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Gross profit | 3 months, 2019-07-01 to 2019-09-30 | $27.4m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2019-01-01 to 2019-09-30 | $85.5m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2019-07-01 to 2019-09-30 | $10.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2019-01-01 to 2019-09-30 | $33.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2019-07-01 to 2019-09-30 | $16.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2019-01-01 to 2019-09-30 | $52.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2019-07-01 to 2019-09-30 | $557.0k | us-gaap:InterestExpense |
| Interest expense | 9 months, 2019-01-01 to 2019-09-30 | $1.5m | us-gaap:InterestExpense |
| Income tax | 3 months, 2019-07-01 to 2019-09-30 | $3.2m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2019-01-01 to 2019-09-30 | $11.2m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2019-07-01 to 2019-09-30 | $9.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2019-01-01 to 2019-09-30 | $32.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2019-07-01 to 2019-09-30 | $0.66 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months, 2019-01-01 to 2019-09-30 | $1.90 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months, 2019-01-01 to 2019-09-30 | $46.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2019-01-01 to 2019-09-30 | $7.4m | us-gaap:PaymentsToAcquireProductiveAssets |
| Dividends paid | 9 months, 2019-01-01 to 2019-09-30 | $10.7m | us-gaap:PaymentsOfDividendsCommonStock |
| Cash and equivalents | at 2019-09-30 | $27.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2019-09-30 | $92.5m | us-gaap:AssetsCurrent |
| Total assets | at 2019-09-30 | $565.2m | us-gaap:Assets |
| Current liabilities | at 2019-09-30 | $62.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2019-09-30 | $188.1m | us-gaap:Liabilities |
| Long-term debt | at 2019-09-30 | $55.3m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2019-09-30 | $718.0k | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2019-09-30 | $235.5m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 47,809 characters.

The following is a discussion of our historical consolidated financial condition and results of operations, and should be read in conjunction with (i) our historical consolidated financial statements and accompanying notes thereto included elsewhere in this Quarterly Report on Form 10-Q; (ii) our Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission (the “SEC”) on March 18, 2019 (“2018 Annual Report”); and (iii) our management’s discussion and analysis of financial condition and results of operations included in our 2018 Annual Report. This discussion includes forward-looking statements that are subject to risk and uncertainties. Actual results may differ substantially from the statements we make in this section due to a number of factors that are discussed in “Forward-Looking Statements” herein and “Part I – Item 1A. Risk Factors” of our 2018 Annual Report.

References to “we,” “us,” “our” and the “Company” shall mean U.S. Physical Therapy, Inc. and its subsidiaries.

### EXECUTIVE SUMMARY

### Our Business

We operate outpatient physical therapy clinics that provide pre- and post-operative care and treatment for a variety of orthopedic-related disorders and sports-related injuries, neurologically-related injuries and rehabilitation of injured workers. At September 30, 2019, we operated 574 clinics in 41 states. In addition to our ownership and operation of outpatient physical therapy clinics, we also manage physical therapy facilities for third parties, such as physicians and hospitals, with 26 such third-party facilities under management as of September 30, 2019.

In March 2017, we purchased a 55.0% interest in our initial industrial injury prevention business. On April 30, 2018, we made a second acquisition and subsequently combined the two businesses. After the combination, we owned a 59.45% interest in the combined business. On April 11, 2019, we acquired a third company that is a provider of industrial injury prevention services. The acquired company specializes in delivering injury prevention and care, post offer employment testing, functional capacity evaluations and return-to-work services. It performs these services across a network in 45 states including onsite at eleven client locations. The business was then combined with Briotix Health, our industrial injury prevention operation, increasing our ownership position in the Briotix Health partnership to approximately 76.0%. The purchase price for the acquisition was $23.6 million, which consisted of $19.6 million in cash (of which $0.5 million remained payable at September 30, 2019 to certain shareholders), and a $4.0 million seller note. The note accrues interest at 5.5% and the principal and accrued interest is payable on April 9, 2021.

Services provided include onsite injury prevention and rehabilitation, performance optimization and ergonomic assessments. The majority of these services are contracted with and paid for directly by employers, including a number of Fortune 500 companies. Other clients include large insurers and their contractors. We perform these services through Industrial Sports Medicine Professionals, consisting of both physical therapists and highly specialized certified athletic trainers (ATCs).

In addition to the above acquired interests in the industrial injury prevention businesses, on August 31, 2018, we acquired a 70% interest in a four-clinic physical therapy practice. The purchase price for the 70% interest was $7.3 million in cash and $400,000 in a seller note that is payable in two principal installments totaling $200,000 each, plus accrued interest. The first installment was paid in August 2019 and the second installment is due in August 2020.

On September 30, 2019, we acquired a 67% interest in eleven-clinic physical therapy practice. The purchase price for the 67% interest was $12.4 million of which $12.1 million was paid in cash and $0.3 million in a seller note that is payable in two principal installments totaling $150,000 each, plus accrued interest in September 2020 and September 2021. The note accrues interest at 5.0% per annum.

In addition, during 2018, through several of our majority owned Clinic Partnerships, we acquired five separate clinic practices. These practices operate as satellites of the existing Clinic Partnership. The aggregate purchase price was $1.0 million inclusive of cash of $850,000 and a note payable of $150,000. The note accrued interest at 4.5% and was paid, principal and accrued interest, on August 31, 2019.

In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) (“ASC 842”), which amended prior accounting standards for leases.

We adopted ASC 842 as of January 1, 2019, which resulted in an increase to total assets and liabilities due to the recording of operating lease right-of-use assets and operating lease liabilities of approximately $78.0 million and $82.6 million respectively, as of January 1, 2019 for operating leases as a lessee. The adoption did not materially impact our consolidated statement of income or cash flows.

### Selected Operating and Financial Data

The following table presents selected operating and financial data that we believe are key indicators of our operating performance.

|  | Three Months Ended September 30, 2019 | September 30, 2018 | Nine Months Ended September 30, 2019 | September 30, 2018 |
| --- | ---: | ---: | ---: | ---: |
| Number of clinics, at the end of period | 574 | 588 | 574 | 588 |
| Working Days | 64 | 63 | 191 | 191 |
| Average visits per day per clinic | 27.5 | 26.6 | 27.5 | 26.4 |
| Total patient visits | 996,063 | 979,875 | 3,055,451 | 2,934,515 |
| Net patient revenue per visit | $104.80 | $105.48 | $106.17 | $105.60 |

### RESULTS OF OPERATIONS

### Three Months Ended September 30, 2019 Compared to the Three Months Ended September 30, 2018

- For the third quarter ended September 30, 2019, our Operating Results (as defined below) increased 11.7% to $9.0 million, or $0.71 per diluted share, as compared to $8.1 million, or $0.64 per diluted share, in the third quarter of 2018. For the nine months ended September 30, 2019, our Operating Results increased 13.7% to $27.8 million, or $2.18 per diluted share, as compared to $24.5 million, or $1.93 per diluted share, in the first nine months of 2018. Operating Results, a non-Generally Accepted Accounting Principle (“GAAP”) measure, equals net income attributable to our shareholders per the consolidated statements of net income less the gain on the sale of a partnership interest as described below. The earnings per share from Operating Results also excludes the impact of the revaluation of redeemable non-controlling interest. On June 30, 2019, the Company sold its 50% interest in one physical therapy partnership to the group’s founders for $11.6 million and recognized a pre-tax gain of $5.8 million on the sale.
- For the third quarter ended September 30, 2019, the net income attributable to our shareholders was $9.0 million, as compared to $8.1 million in the third quarter of 2018. Inclusive of the charge for revaluation of non-controlling interest, net of tax, used to compute diluted earnings per share, in accordance with GAAP, in the recent quarter, the amount is $8.4 million, or $0.66 per share, as compared to $1.7 million, or $0.13 per share for the third quarter of 2018. In accordance with current accounting guidance, the revaluation of redeemable non-controlling interest, net of tax, is not included in net income but charged directly to retained earnings but is included in the earnings per basic and diluted share calculation.

The following table provides details of the diluted earnings per share computation and reconciles net income attributable to our shareholders calculated in accordance with GAAP to Operating Results. Management believes providing Operating Results to investors is useful information for comparing our period-to-period results. Operating Results per share, a non-GAAP measure, equals net income attributable to our shareholders per the consolidated statement of net income, and excludes the impact of the gain on the sale of a partnership interest and the revaluation of redeemable non-controlling interest, net of tax, to calculate earnings per share. In accordance with current accounting guidance, the revaluation of redeemable non-controlling interest, net of tax, is not included in net income but charged directly to retained earnings and is included in the earnings per basic and diluted share calculation. Management uses Operating Results, which eliminates certain items described above that can be subject to volatility and unusual costs, as one of the principal measures to evaluate and monitor financial performance period over period. Management believes that Operating Results is useful information for investors to use in comparing our period-to-period results as well as for comparing with other similar businesses since most do not have redeemable non-controlling interest instruments and therefore have different liability and equity structures.

Operating Results is not a measure of financial performance under GAAP. Operating Results should not be considered in isolation or as an alternative to, or substitute for, net income attributable to our shareholders presented in the consolidated financial statements.

| Computation of earnings per share - USPH shareholders: | Three Months Ended September 30, 2019 | 2018 |
| --- | ---: | ---: |
| Net income attributable to USPH shareholders | $9,047 | $8,102 |
| Charges to retained earnings: |  |  |
| Revaluation of redeemable non-controlling interest | (922) | (8,680) |
| Tax effect at statutory rate (federal and state) of 26.25% | 242 | 2,279 |
|  | $8,367 | $1,701 |
| Earnings per share (basic and diluted) | $0.66 | $0.13 |
| Adjustments: |  |  |
| Gain on sale of partnership interest | - | - |
| Revaluation of redeemable non-controlling interest | 922 | 8,680 |
| Tax effect at statutory rate (federal and state) of 26.25% | (242) | (2,279) |
| Operating Results | $9,047 | $8,102 |
| Basic and diluted Operating Results per share | $0.71 | $0.64 |
| Shares used in computation - basic and diluted | 12,774 | 12,685 |

### Revenues

- Net revenues increased $4.1 million or 3.7% from $113.1 million in the 2018 Third Quarter to $117.2 million in the 2019 Third Quarter, due to an increase in net patient revenues from physical therapy operations, internal growth, new clinic development and an acquisition, and an increase in the revenue from the industrial injury prevention business, due to internal growth and an acquisition. Included in the 2018 Third Quarter was revenue of $5.9 million for clinics within the partnership sold on June 30, 2019. The 2019 Third Quarter had 64 business days versus 63 in the 2018 Third Quarter.
- Despite the loss of net patient revenues in the clinics of the sold partnership mentioned previously, net patient revenues from physical therapy operations increased approximately $1.0 million, or 1.0%, to $104.4 million in the 2019 Third Quarter from $103.4 million in the 2018 Third Quarter due to an increase in total patient visits of 1.7% from 980,000 to 996,000 offset by a decrease in the average net patient revenue per visit of $0.68 to $104.80 from $105.48. The reduction in net rate is largely attributable to an $825,000 overpayment relating to a single payor for one partnership of which $525,000 affected the third quarter of 2019. The overpayment was discovered by management this summer. It occurred over several years and following a thorough review was accounted for in the two recent quarterly periods. Of the $1.0 million increase in net patient revenues, $1.6 million of the increase related to clinics opened or acquired after September 30, 2018 (“New Clinics”). Net patient revenues related to clinics opened or acquired prior to October 1, 2018 excluding the clinics sold (“Mature Clinics”) increased by $5.3 million. Net patient revenues related to the clinics sold was $5.9 million in the 2018 Third Quarter. Revenue from physical therapy management contracts was $2.2 million for the 2019 Third Quarter and $1.9 million for the 2018 Third Quarter.
- Revenue from the industrial injury prevention business increased 36.6% to $9.9 million in the 2019 Third Quarter compared to $7.3 million in the 2018 Third Quarter due to internal growth and an acquisition in April 2019.
- Other miscellaneous revenue was $0.7 million in the 2019 Third Quarter and $0.6 million in the 2018 Third Quarter.

Net patient revenues are based on established billing rates less allowances for patients covered by contractual programs and workers’ compensation. Net patient revenues are determined after contractual and other adjustments relating to patient discounts from certain payors. Payments received under contractual programs and workers’ compensation are based on predetermined rates and are generally less than the established billing rates.

### Operating Costs

Total operating costs were $89.9 million, or 76.7% of net revenues, in the 2019 Third Quarter as compared to $87.1 million, or 76.9% of net revenues, in the 2018 Third Quarter. The $2.8 million increase was attributable to $3.9 million in operating costs related to New Clinics, an increase of $1.4 million related to Mature Clinics, an increase of $0.2 million related to management contracts and an increase of $2.8 million related to the industrial injury prevention business including a recent acquisition and $0.3 million in integration costs incurred related to the recent acquisition. These increases were offset by a reduction in expenses related to the clinics sold of $5.5 million. Each component of operating costs is discussed below:

### Operating Costs—Salaries and Related Costs

Salaries and related costs increased to $66.7 million for the 2019 Third Quarter from $64.5 million for the 2018 Third Quarter, an increase of $2.2 million. Salaries and related costs for New Clinics amounted to $1.1 million for the 2019 Third Quarter. Salaries and related costs for the industrial injury prevention business was $6.3 million in the 2019 Third Quarter compared to $4.2 million 2018 Third Quarter, an increase of $2.1 million primarily due to the acquisition in April 2019. For Mature Clinics, salaries and related costs increased by $3.2 million for the 2019 Third Quarter compared to the 2018 Third Quarter. For management contracts, salaries and related costs remained relatively the same for the 2019 Third Quarter compared to the 2018 Third Quarter. Salaries and related costs related to the clinics in the partnership sold was $4.2 million for the 2018 Third Quarter. Salaries and related costs as a percentage of net revenues were 56.9% for the 2019 Third Quarter and 57.0% for the 2018 Third Quarter.

### Operating Costs—Rent, Supplies, Contract Labor and Other

Rent, supplies, contract labor and other were $22.2 million for the 2019 Third Quarter and $21.7 million for the 2018 Third Quarter. For New Clinics, rent, supplies, contract labor and other amounted to $0.6 million for the 2019 Third Quarter. For Mature Clinics, rent, supplies, contract labor and other increased by $0.1 million in the 2019 Third Quarter compared to the 2018 Third Quarter and for the industrial injury prevention business increased by $1.0 million for the respective periods. For management contracts, rent, supplies, contract labor and other increased by $0.1 million for the 2019 Third Quarter compared to the 2018 Third Quarter. Rent, supplies, contract labor and other related to the clinics in the partnership sold was $1.3 million for the 2018 Third Quarter. Rent, supplies, contract labor and other as a percentage of net revenues was 18.9% for the 2019 Third Quarter and 19.1 % for the 2018 Third Quarter.

### Operating Costs—Provision for Doubtful Accounts

The provision for doubtful accounts was $1.0 million for the 2019 Third Quarter and $0.9 million for the 2018 Third Quarter. The provision for doubtful accounts for patient accounts receivable as a percentage of net patient revenues was 0.8% for both the 2019 Third Quarter and 2018 comparable periods.

Our provision for doubtful accounts for patient accounts receivable as a percentage of total patient accounts receivable was 5.17% at September 30, 2019, as compared to 5.63% at December 31, 2018. Our days’ sales outstanding was 34 days at September 30, 2019 and 37 days at December 31, 2018.

### Gross Profit

The gross profit for the 2019 Third Quarter grew by 5.0% or $1.3 million, to $27.4 million, as compared to $26.1 million in the 2018 Third Quarter. The gross profit percentage was 23.3% of net revenue in the most recent period as compared to 23.1% in the 2018 Third Quarter. The gross profit percentage for our physical therapy clinics was 23.9% in the recent quarter as compared to 22.8% in the 2018 Third Quarter. The gross profit percentage for the industrial injury prevention business was 19.9% in the recent quarter as compared to 29.7% in the 2018 Third Quarter. The gross profit percentage on physical therapy management contracts was 11.2% in the 2019 Third Quarter as compared to 9.9% in the 2018 Third Quarter.

### Corporate Office Costs

Corporate office costs, consisting primarily of salaries, incentive compensation, and benefits of corporate office personnel, rent, insurance costs, depreciation and amortization, travel, legal, accounting, professional, and recruiting fees, were $10.6 million for the 2019 Third Quarter and for the 2018 Third Quarter. As a percentage of net revenues, corporate office costs were 9.0% for the 2019 Third Quarter and 9.4% for the 2018 Third Quarter.

### Operating Income

Operating income for the 2019 Third Quarter increased 9.0% to $16.8 million as compared to $15.4 million in the 2018 Third Quarter.

### Interest Expense

Interest expense was $0.6 million in the 2019 Third Quarter and in the 2018 Third Quarter due to higher average borrowings under our revolving credit line. At September 30, 2019, $51.0 million was outstanding under our Amended Credit Agreement. See “—Liquidity and Capital Resources” below for a discussion of the terms of our Amended Credit Agreement.

### Provision for Income Taxes

The provision for income taxes for the 2019 Third Quarter was $3.2 million and for the 2018 Third Quarter was $3.0 million. The provision for income tax as a percentage of income before taxes less net income attributable to non-controlling interest was 26.1% and 27.0%, respectively, for the 2019 Third Quarter and 2018 Third Quarter.

See table below detailing calculation of the provision for income tax as a percentage of income before taxes less net income attributable to non-controlling interest ($ in thousands):

|  | Three Months Ended September 30, 2019 | September 30, 2018 |
| --- | ---: | ---: |
| Income before taxes | $16,266 | $14,870 |
| Less: net income attributable to non-controlling interests: |  |  |
| Non-controlling interests - permanent equity | (1,643) | (1,321) |
| Redeemable non-controlling interests - temporary equity | (2,379) | (2,456) |
|  | $(4,022) | $(3,777) |
| Income before taxes less net income attributable to non-controlling interests | $12,244 | $11,093 |
| Provision for income taxes | $3,197 | $2,991 |
| Percentage | 26.1% | 27.0% |

### Net Income Attributable to Non-controlling Interests

Net income attributable to non-controlling interests (permanent equity) was $1.6 million in the 2019 Third Quarter and $1.3 million in the 2018 Third Quarter. Net income attributable to redeemable non-controlling interests (temporary equity) was $2.4 million in the 2019 Third Quarter and $2.5 million in the 2018 Third Quarter.

### Nine Months Ended September 30, 2019 Compared to the Nine Months Ended September 30, 2018

- For the nine months ended September 30, 2019 (“2019 First Nine Months”), our Operating Results increased 13.7% to $27.8 million, or $2.18 per diluted share, as compared to $24.5 million, or $1.93 per diluted share during the nine months ended September 30, 2018 (the “2018 First Nine Months” Operating Results, a non-GAAP measure, equals net income attributable to our shareholders per the consolidated statements of net income less the gain on the sale of a partnership interest as described below. The earnings per share from Operating Results also excludes the impact of the revaluation of redeemable non-controlling interest. On June 30, 2019, the Company sold its 50% interest in one physical therapy partnership to the group’s founders for $11.6 million and recognized a pre-tax gain of $5.8 million on the sale.
- For the 2019 First Nine Months, our net income attributable to its shareholders, in accordance with GAAP, was $32.1 million as compared to $24.5 million for the comparable period of 2018. Inclusive of the charge for revaluation of non-controlling interest, net of tax, used to compute diluted earnings per share, in accordance with GAAP, in the recent nine months, the amount is $24.2 million, or $1.90 per share, as compared to $11.1 million, or $0.88 per share for the 2018 First Nine Months. In accordance with current accounting guidance, the revaluation of redeemable non-controlling interest, net of tax, is not included in net income but charged directly to retained earnings but is included in the earnings per basic and diluted share calculation.

The following table provides details of the diluted earnings per share computation and reconciles net income attributable to our shareholders calculated in accordance with GAAP to Operating Results. Management believes providing Operating Results to investors is useful information for comparing our period-to-period results. Operating Results (as defined below), a non-GAAP measure, equals net income attributable to our shareholders per the consolidated statements of net income, and excludes the impact of the gain on the sale of a partnership interest and the revaluation of redeemable non-controlling interest to calculate the Operating Results per share. In accordance with current accounting guidance, the revaluation of redeemable non-controlling interest, net of tax, is not included in net income but charged directly to retained earnings and is included in the earnings per basic and diluted share calculation. Management uses Operating Results, which eliminates certain items described above that can be subject to volatility and unusual costs, as one of the principal measures to evaluate and monitor financial performance period over period. Management believes that Operating Results is useful information for investors to use in comparing our period-to-period results as well as for comparing with other similar businesses since most do not have redeemable non-controlling interest instruments and therefore have different liability and equity structures.

Operating Results is not a measure of financial performance under GAAP. Operating Results should not be considered in isolation or as an alternative to, or substitute for, net income attributable to our shareholders.

| Computation of earnings per share - USPH shareholders: | Nine Months Ended September 30, 2019 | 2018 |
| --- | ---: | ---: |
| Net income attributable to USPH shareholders | $32,110 | $24,465 |
| Charges to retained earnings: |  |  |
| Revaluation of redeemable non-controlling interest | (10,752) | (18,105) |
| Tax effect at statutory rate (federal and state) of 26.25% | 2,822 | 4,753 |
|  | $24,180 | $11,113 |
| Earnings per share (basic and diluted) | $1.90 | $0.88 |
| Adjustments: |  |  |
| Gain on sale of partnership interest | (5,823) | - |
| Revaluation of redeemable non-controlling interest | 10,752 | 18,105 |
| Tax effect at statutory rate (federal and state) of 26.25% | (1,293) | (4,753) |
| Operating Results | $27,816 | $24,465 |
| Basic and diluted Operating Results per share | $2.18 | $1.93 |
| Shares used in computation - basic and diluted | 12,750 | 12,660 |

### Revenues

- Net revenues increased $23.3 million, or 6.9% from $336.6 million in the First Nine Months of 2018 to $359.9 million in the 2019 First Nine Months, primarily due to an increase in net patient revenues from physical therapy operations due to internal growth and new clinic development plus an acquisition, and an increase in the revenue from the industrial injury prevention business due to internal growth and acquisitions. Both the 2019 and 2018 First Nine Months had 191 business days.
- Net patient revenues from physical therapy operations increased approximately $14.5 million, or 4.7%, to $324.4 million in the 2019 First Nine Months from $309.9 million in the 2018 First Nine Months due to an increase in total patient visits of 4.1% from 2,935,000 to 3,055,000 and an increase in the average net patient revenue per visit to $106.17 from $105.60. The net rate was affected by an $825,000 overpayment relating to a single payor for one partnership. The overpayment was discovered by management this summer. It occurred over several years and following a thorough review was accounted for in the two recent quarterly periods. Of the $14.5 million increase in net patient revenues, $16.5 million related to Mature Clinics and $3.7 million related to New Clinics. The net patient revenues related to the clinics sold on June 30, 2019 had the effect of reducing total net revenues by $5.7 million in the 2019 First Nine Months (only six months included - $17.9 million) compared to the same period in 2018 (nine months included - $12.2 million). Revenue from physical therapy management contracts was $6.5 million for the 2019 First Nine Months and $6.3 million for the 2018 comparable period.
- Revenue from the industrial injury prevention business increased 47.4% to $27.1 million in the 2019 First Nine Months compared to $18.4 million in the 2018 First Nine Months due to internal growth and recent acquisitions.
- Other miscellaneous revenue was $1.8 million in the 2019 First Nine Months and $1.9 million in the 2018 First Nine Months.

Net patient revenues are based on established billing rates less allowances for patients covered by contractual programs and workers’ compensation. Net patient revenues are determined after contractual and other adjustments relating to patient discounts from certain payors. Payments received under contractual programs and workers’ compensation are based on predetermined rates and are generally less than the established billing rates.

### Operating Costs

Total operating costs were $274.3 million, or 76.2% of net revenues, in the 2019 First Nine Months as compared to $260.1 million, or 77.3% of net revenues, in the 2018 First Nine Months. The $14.2 million increase was attributable to $7.9 million in operating costs related to Mature Clinics, an increase of $4.1 million related to New Clinics, an increase of $6.9 million related to the industrial injury prevention business and an increase in management contracts costs of $0.6 million offset by a reduction in expenses related to the clinics sold of $5.3 million. Each component of operating costs is discussed below:

### Operating Costs—Salaries and Related Costs

Salaries and related costs increased to $203.7 million for the 2019 First Nine Months from $191.4 million for the 2018 First Nine Months, an increase of $12.3 million. Salaries and related costs for New Clinics amounted to $2.5 million for the 2019 First Nine Months. Salaries and related costs for the industrial injury prevention business was $16.7 million in the 2019 First Nine Months compared to $11.4 million in the 2018 First Nine Months, an increase of $5.3 million. For Mature Clinics, salaries and related costs increased by $8.4 million for the 2019 First Nine Months compared to the 2018 First Nine Months. For management contracts, salaries and related costs increased by $0.1 million for the 2019 Third Quarter compared to the 2018 Third Quarter. Salaries and related costs related to the clinics in the partnership sold reduced by $4.0 million for the 2019 First Nine Months (six months of operations) compared to the 2018 First Nine Months (nine months of operations). Salaries and related costs as a percentage of net revenues were 56.6% for the 2019 First Nine Months and 56.9% for the 2018 First Nine Months.

### Operating Costs—Rent, Supplies, Contract Labor and Other

Rent, supplies, contract labor and other were $67.2 million for the 2019 First Nine Months and $65.6 million for the 2018 First Nine Months. For New Clinics, rent, supplies, contract labor and other amounted to $1.5 million for the 2019 First Nine Months. For Mature Clinics, rent, supplies, contract labor and other decreased by $0.3 million in the 2019 First Nine Months compared to the 2018 First Nine Months and for the industrial injury prevention business increased by $1.6 million for the respective periods. For management contracts, rent, supplies, contract labor and other remained relatively the same for the 2019 First Nine Months compared to the 2018 First Nine Months. Rent, supplies, contract labor and other related to the clinics in the partnership sold reduced by $1.2 million for the 2019 First Nine Months (six months of operations) compared to the 2018 First Nine Months (nine months of operations). Rent, supplies, contract labor and other as a percentage of net revenues was 18.7% for the 2019 First Nine Months and 19.5% for the 2018 First Nine Months.

### Operating Costs—Provision for Doubtful Accounts

The provision for doubtful accounts was $3.4 million for the 2019 First Nine Months and $3.1 million for the 2018 First Nine Months. The provision for doubtful accounts for patient accounts receivable as a percentage of net patient revenues was 0.9% both for the 2019 First Nine Months and 2018 First Nine Months.

Our provision for doubtful accounts for patient accounts receivable as a percentage of total patient accounts receivable was 5.17% at September 30, 2019, as compared to 5.63% at December 31, 2018. Our day’s sales outstanding remained at 34 days at September 30, 2019 and 37 days at December 31, 2018.

### Gross Profit

The gross profit for the 2019 First Nine Months grew by 11.9% or $9.1 million to $85.5 million, as compared to $76.4 million in the 2018 First Nine Months. The gross profit percentage was 23.8% of net revenue in the most recent period as compared to 22.7% in the 2018 First Nine Months. The gross profit percentage for our physical therapy clinics was 23.9% in the recent quarter as compared to 22.6% in the 2018 First Nine Months. The gross profit percentage for the industrial injury prevention business was 24.0% in the recent quarter as compared to 24.2% in the 2018 First Nine Months. The gross profit percentage on physical therapy management contracts was 15.0% in the 2019 First Nine Months as compared to 22.0% in the 2018 First Nine Months.

### Corporate Office Costs

Corporate office costs, consisting primarily of salaries, incentive compensation, and benefits of corporate office personnel, rent, insurance costs, depreciation and amortization, travel, legal, accounting, professional, and recruiting fees, were $33.4 million for the 2019 First Nine Months and $30.9 million for the 2018 First Nine Months. As a percentage of net revenues, corporate office costs were 9.3% for the 2019 First Nine Months and 9.2% for the 2018 First Nine Months.

### Operating Income

Operating income for the 2019 First Nine Months increased 14.6% to $52.1 million as compared to $45.5 million in the 2018 First Nine Months. Operating income as a percentage of net revenue was 13.5% in the 2018 period and 14.5% in the 2019 First Nine Months.

### Gain on sale of partnership interest

The gain of $5.8 million in the 2019 First Nine Months resulted from a sale of partnership interest. As previously disclosed, on June 30, 2019, we sold a 50% interest in one physical therapy partnership to the group’s founders. The sales proceeds, all of which was in cash, was $11.6 million.

### Interest Expense

Interest expense was $1.5 million in the 2019 First Nine Months and $1.7 million in the 2018 First Nine Months. At September 30, 2019, $51.0 million was outstanding under our Amended Credit Agreement. See “—Liquidity and Capital Resources” below for a discussion of the terms of our Amended Credit Agreement.

### Provision for Income Taxes

The provision for income taxes for the 2019 First Nine Months was $11.2 million and for the 2018 First Nine Months was $8.7 million. The provision for income tax as a percentage of income before taxes less net income attributable to non-controlling interest was 25.9% and 26.3%, respectively, for the 2019 First Nine Months and 2018 First Nine Months.

See table below detailing calculation of the provision for income tax as a percentage of income before taxes less net income attributable to non-controlling interest ($ in thousands):

|  | Nine Months Ended September 30, 2019 | September 30, 2018 |
| --- | ---: | ---: |
| Income before taxes | $56,467 | $43,903 |
| Less: net income attributable to non-controlling interests: |  |  |
| Non-controlling interests - permanent equity | (4,982) | (3,902) |
| Redeemable non-controlling interests - temporary equity | (8,152) | (6,802) |
|  | $(13,134) | $(10,704) |
| Income before taxes less net income attributable to non-controlling interests | $43,333 | $33,199 |
| Provision for income taxes | $11,223 | $8,734 |
| Percentage | 25.9% | 26.3% |

### Net Income Attributable to Non-controlling Interests

Net income attributable to non-controlling interests (permanent equity) was $5.0 million in the 2019 First Nine Months and $3.9 million in the 2018 First Nine Months. Net income attributable to redeemable non-controlling interests (temporary equity) was $8.2 million in the 2019 First Nine Months and $6.8 million in the 2018 First Nine Months.

### LIQUIDITY AND CAPITAL RESOURCES

We believe that our business is generating sufficient cash flow from operations to allow us to meet our short-term and long-term cash requirements, other than those with respect to future acquisitions. At September 30, 2019 and December 31, 2018, we had $27.8 million and $23.4 million, respectively, in cash. Although the start-up costs associated with opening new clinics and our planned capital expenditures are significant, we believe that our cash and unused availability under our revolving credit agreement are sufficient to fund the working capital needs of our operating subsidiaries, future clinic development and acquisitions and investments through at least September 2020. Significant acquisitions would likely require additional financing.

Effective December 5, 2013, we entered into an Amended and Restated Credit Agreement with a commitment for a $125.0 million revolving credit facility. This agreement was amended in August 2015, January 2016, March 2017 and November 2017 (hereafter referred to as “Amended Credit Agreement”). The Amended Credit Agreement is unsecured and has loan covenants, including requirements that we comply with a consolidated fixed charge coverage ratio and consolidated leverage ratio. Proceeds from the Amended Credit Agreement may be used for working capital, acquisitions, purchases of our common stock, dividend payments to our common stockholders, capital expenditures and other corporate purposes. The pricing grid is based on our consolidated leverage ratio with the applicable spread over LIBOR ranging from 1.25% to 2.0% or the applicable spread over the Base Rate ranging from 0.1% to 1%. Fees under the Amended Credit Agreement include an unused commitment fee ranging from 0.25% to 0.3% depending on our consolidated leverage ratio and the amount of funds outstanding under the Amended Credit Agreement.

The January 2016 amendment to the Amended Credit Agreement increased the cash and noncash consideration that we could pay with respect to acquisitions permitted under the Amended Credit Agreement to $50.0 million for any fiscal year, and increased the amount we may pay in cash dividends to our shareholders in an aggregate amount not to exceed $10.0 million in any fiscal year. The March 2017 amendment, among other items, increased the amount we may pay in cash dividends to our shareholders in an aggregate amount not to exceed $15.0 million in any fiscal year. The November 2017 amendment, among other items, adjusted the pricing grid as described above, increased the aggregate amount we may pay in cash dividends to $20.0 million to our shareholders and extended the maturity date to November 30, 2021.

Cash and cash equivalents increased by $4.5 million from December 31, 2018 to September 30, 2019. During the 2019 First Nine Months, $46.5 million was provided by operations, $11.6 million proceeds on sale of a partnership interest, and $13.0 million of net proceeds from our revolving line of credit. The major uses of cash for investing and financing activities included: purchases of majority interests in businesses ($30.4 million), distributions to non-controlling interests inclusive of those classified as redeemable non-controlling interests ($10.9 million), cash dividends paid to shareholders ($10.7 million), purchase of fixed assets ($7.4 million), purchase of redeemable non-controlling interests ($5.7 million) and payments on notes payable ($1.4 million).

On September 30, 2019, we acquired a 67% interest in eleven-clinic physical therapy practice. The purchase price for the 67% interest was $12.4 million, of which $12.1 million was in cash and $0.3 million in a seller note that is payable in two principal installments totaling $150,000 each, plus accrued interest in September 2020 and September 2021. The note accrues interest at 5.0% per annum.

On April 11, 2019, we acquired a company that is a provider of industrial injury prevention services. The acquired company specializes in delivering injury prevention and care, post offer employment testing, functional capacity evaluations and return-to-work services. The purchase price was $23.6 million in cash, which consisted of $19.6 million in cash (of which $0.5 million remained payable at September 30, 2019 to certain shareholders), and a $4.0 million seller note. The principal and accrued interest on the seller note is payable in April 2021.

On March 4, 2019, in conjunction with the purchase of a redeemable non-controlling interest, we entered into a note payable in the amount of $228,120 that is payable in two principal installments of $114,080 each, plus accrued interest, in March 2020 and 2021.

On February 28, 2018, through one of our majority owned partnerships, we acquired the assets and business of two physical therapy clinics, for an aggregate purchase price of $760,000 in cash and $150,000 in seller note that was paid, plus accrued interest, in August 2019.

On April 30, 2018, we purchased a 65% interest in the assets and business of industrial injury prevention services, for an aggregate purchase price of $8.6 million in cash and $400,000 in seller note that is payable, plus accrued interest, on April 30, 2019. The initial industrial injury prevention business was acquired in March 2017 and, on April 30, 2018, we made a second acquisition with the two businesses then combined. After the combination, we own a 59.45% interest in the combined business.

On August 31, 2018 we acquired a 70% interest in a four-clinic physical therapy practice. The purchase price for the 70% interest was $7.3 million in cash and $400,000 in a seller note that is payable in two principal installments totaling $200,000 each, plus accrued interest. The first installment was paid in August 2019 and the second installment remains payable in August 2020.

Historically, we have generated sufficient cash from operations to fund our development activities and to cover operational needs. We plan to continue developing new clinics and making additional acquisitions. We also from time to time purchase the non-controlling interests in our Clinic Partnerships. Generally, any acquisition or purchase of non-controlling interests is expected to be accomplished using a combination of cash and financing. Any large acquisition would likely require financing.

We make reasonable and appropriate efforts to collect accounts receivable, including applicable deductible and co-payment amounts, in a consistent manner for all payor types. Claims are submitted to payors daily, weekly or monthly in accordance with our policy or payor’s requirements. When possible, we submit our claims electronically. The collection process is time consuming and typically involves the submission of claims to multiple payors whose payment of claims may be dependent upon the payment of another payor. Claims under litigation and vehicular incidents can take a year or longer to collect. Medicare and other payor claims relating to new clinics awaiting Medicare Rehab Agency status approval initially may be delayed for a relatively short transition period. When all reasonable internal collection efforts have been exhausted, accounts are written off prior to sending them to outside collection firms. With managed care, commercial health plans and self-pay payor type receivables, the write-off generally occurs after the accounts receivable has been outstanding for at least 120 days.

We generally enter into various notes payable as a means of financing our acquisitions. Our outstanding notes payable as of September 30, 2019 relate to certain of the acquisitions of businesses and purchases of redeemable non-controlling interests that occurred in 2017 through September 2019. Typically, the notes are payable over two years plus any accrued and unpaid interest. Interest accrues at various interest rates ranging from 3.25% to 5.5% per annum, subject to adjustment. At September 30, 2019, the balance on these notes payable was $5.1 million. In addition, we assumed leases with remaining terms of 1 month to 6 years for the operating facilities.

In conjunction with the above mentioned acquisitions, in the event that a limited minority partner’s employment ceases at any time after a specified date that is typically between three and five years from the acquisition date, we have agreed to certain contractual provisions which enable such minority partners to exercise their right to trigger our repurchase of that partner’s non-controlling interest at a predetermined multiple of earnings before interest and taxes.

As of September 30, 2019, we have accrued $5.0 million related to credit balances due to patients and payors. This amount is expected to be paid in the next twelve months.

From September 2001 through December 31, 2008, our Board of Directors (“Board”) authorized us to purchase, in the open market or in privately negotiated transactions, up to 2,250,000 shares of our common stock. In March 2009, the Board authorized the repurchase of up to 10% or approximately 1,200,000 shares of our common stock (“March 2009 Authorization”). Our Amended Credit Agreement permits share repurchases of up to $15,000,000, subject to compliance with covenants. We are required to retire shares purchased under the March 2009 Authorization.

There is no expiration date for the share repurchase program. As of September 30, 2019, there are currently an additional estimated 114,899 shares (based on the closing price of $130.55 on September 30, 2019) that may be purchased from time to time in the open market or private transactions depending on price, availability and our cash position. We did not purchase any shares of our common stock during the nine months ended September 30, 2019.

### FACTORS AFFECTING FUTURE RESULTS

The risks related to our business and operations include:

- changes as the result of government enacted national healthcare reform;
- changes in Medicare rules and guidelines and reimbursement or failure of our clinics to maintain their Medicare certification and/or enrollment status;
- revenue we receive from Medicare and Medicaid being subject to potential retroactive reduction;
- business and regulatory conditions including federal and state regulations;
- governmental and other third party payor inspections, reviews, investigations and audits; which may result in sanctions or reputable harm and increased costs;
- compliance with federal and state laws and regulations relating to the privacy of individually identifiable patient information, and associated fines and penalties for failure to comply;
- changes in reimbursement rates or payment methods from third party payors including government agencies and changes in the deductibles and co-pays owed by patients;
- revenue and earnings expectations;
- legal actions, which could subject us to increased operating costs and uninsured liabilities;
- general economic conditions;
- availability and cost of qualified physical therapists;
- personnel productivity and retaining key personnel;
- competitive, economic or reimbursement conditions in our markets which may require us to reorganize or close certain clinics and thereby incur losses and/or closure costs including the possible write-down or write-off of goodwill and other intangible assets;
- acquisitions, purchase of non-controlling interests (minority interests) and the successful integration of the operations of the acquired businesses;
- maintaining our information technology systems with adequate safeguards to protect against cyber-attacks;
- a security breach of our or our third party vendors’ information technology systems may subject us to potential legal action and reputational hard and may result in a violation of the Health Insurance Portability and Accountability Act of 1996 of the Health Information Technology for Economic and Clinical Health Act;
- maintaining adequate internal controls;
- maintaining necessary insurance coverage;
- availability, terms, and use of capital; and
- weather and other seasonal factors.

See Risk Factors in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2018.

### Forward-Looking Statements

We make statements in this report that are considered to be forward-looking statements within the meaning given such term under Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements contain forward-looking information relating to the financial condition, results of operations, plans, objectives, future performance and business of our Company. These statements (often using words such as “believes”, “expects”, “intends”, “plans”, “appear”, “should” and similar words) involve risks and uncertainties that could cause actual results to differ materially from those we project. Included among such statements are those relating to opening new clinics, availability of personnel and the reimbursement environment. The forward-looking statements are based on our current views and assumptions and actual results could differ materially from those anticipated in such forward-looking statements as a result of certain risks, uncertainties, and factors, which include, but are not limited to the risks listed above.

Many factors are beyond our control. Given these uncertainties, you should not place undue reliance on our forward-looking statements. Please see the other sections of this report and our other periodic reports filed with the Securities and Exchange Commission (the “SEC”) for more information on these factors. Our forward-looking statements represent our estimates and assumptions only as of the date of this report. Except as required by law, we are under no obligation to update any forward-looking statement, regardless of the reason the statement may no longer be accurate.

## Market risk

As filed, 591 characters.

We do not maintain any derivative instruments, interest rate swap arrangements, hedging contracts, futures contracts or the like. Our primary market risk exposure is the changes in interest rates obtainable on our Amended Credit Agreement. The interest on our Amended Credit Agreement is based on a variable rate. At September 30, 2019, $51.0 million was outstanding under our Amended Credit Agreement. Based on the balance of the Amended Credit Agreement at September 30, 2019, any change in the interest rate of 1% would yield a decrease or increase in annual interest expense of $510,000.

## Controls and procedures

As filed, 1,803 characters.

(a) Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, the Company’s management completed an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures. Based on this evaluation, our principal executive officer and principal financial officer concluded (i) that our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure and (ii) that our disclosure controls and procedures are effective.

(b) Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. During the first quarter of 2019, we implemented internal controls to ensure we have adequately evaluated our contracts and properly assessed the impact of new accounting standards related to leases on our financial statements to facilitate the adoption of such standards on January 1, 2019. There were no significant changes to our internal control over financial reporting due to the adoption of the new standards.

Filed Nov 8, 2019.
Source: SEC EDGAR, the filing index for accession 0001140361-19-020161. Last ingested by Listed: Nov 14, 2026, 13:45 ET. No prices; not investment advice.
